Stock Rating: Liberum Gives AstraZeneca (NYSE:AZN) a Better Buy Rating

November 25, 2016 - By Clifton Ray

Stock Rating:  Liberum Gives AstraZeneca (NYSE:AZN) a Better Buy Rating

AstraZeneca (NYSE:AZN) Upgrade

Liberum raised the shares of AstraZeneca (NYSE:AZN) from a Hold rating to Buy rating in a an analyst note revealed to clients on Friday morning.

AstraZeneca plc (ADR) (NYSE:AZN) Ratings Coverage

Out of 17 analysts covering AstraZeneca plc (ADR) (NYSE:AZN), 11 rate it a “Buy”, 1 “Sell”, while 5 “Hold”. This means 65% are positive. $50 is the highest target while $32 is the lowest. The $38.40 average target is 42.06% above today’s ($27.03) stock price. AstraZeneca plc (ADR) has been the topic of 20 analyst reports since July 31, 2015 according to StockzIntelligence Inc. Deutsche Bank upgraded AstraZeneca plc (ADR) (NYSE:AZN) on Monday, September 14 to “Buy” rating. The company was downgraded on Tuesday, March 15 by Jefferies. Nordea downgraded the shares of AZN in a report on Monday, November 2 to “Hold” rating. The firm earned “Buy” rating on Friday, February 26 by Cantor Fitzgerald. The firm earned “Top Pick” rating on Tuesday, January 26 by Oddo & Cie. The stock has “Buy” rating given by Jefferies on Monday, September 12. The company was maintained on Monday, May 2 by Leerink Swann. HSBC upgraded AstraZeneca plc (ADR) (NYSE:AZN) on Wednesday, September 2 to “Buy” rating. The rating was upgraded by Morgan Stanley on Tuesday, December 1 to “Overweight”. The stock of AstraZeneca plc (ADR) (NYSE:AZN) has “Overweight” rating given on Friday, September 23 by Piperjaffray.

About 7.28 million shares traded hands or 1.82% up from the average. AstraZeneca plc (ADR) (NYSE:AZN) has declined 12.39% since April 22, 2016 and is downtrending. It has underperformed by 17.80% the S&P500.

Analysts await AstraZeneca plc (ADR) (NYSE:AZN) to report earnings on February, 2. They expect $0.57 earnings per share, down 39.36% or $0.37 from last year’s $0.94 per share. AZN’s profit will be $1.43 billion for 11.86 P/E if the $0.57 EPS becomes a reality. After $1.32 actual earnings per share reported by AstraZeneca plc (ADR) for the previous quarter, Wall Street now forecasts -56.82% negative EPS growth.

AstraZeneca PLC is a biopharmaceutical company. The company has a market cap of $67.75 billion. The Firm focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas. It has a 27.75 P/E ratio. The Firm has its activities in over 100 countries.

According to Zacks Investment Research, “AstraZeneca PLC is one of the top five pharmaceutical companies in the world based on sales and is a therapeutic leader in cardiovascular, gastrointestinal, oncology, anesthesia including pain management, central nervous system (CNS) and respiratory products. They are engaged in the research, development, manufacture and marketing of ethical (prescription) pharmaceuticals and agricultural products, and the supply of healthcare services.”

AZN Company Profile

AstraZeneca PLC (AstraZeneca), incorporated on June 17, 1992, is a biopharmaceutical company. The Firm focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas. The Firm has its activities in over 100 countries. The Company’s pipeline includes over 150 projects of which approximately 125 are in the clinical phase of development.

Another recent and important AstraZeneca plc (ADR) (NYSE:AZN) news was published by Businessfinancenews.com which published an article titled: “AstraZeneca plc (ADR): What Are the Future Prospects?” on August 01, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Tags:

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>